Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma

BACKGROUND: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma pati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ecancermedicalscience
Egile Nagusiak: Kumar, Gunjesh, DSouza, Hollis, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Boppana, Mounika, Rajpurohit, Annu, Mahajan, Abhishek, Janu, Amit, Chatterjee, Abhishek, Krishnatry, Rahul, Gupta, Tejpal, Jalali, Rakesh, Patil, Vijay M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cancer Intelligence 2021
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929766/
https://ncbi.nlm.nih.gov/pubmed/33680080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2021.1166
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak